Results
1 -
4 of
4Inhibitors of the JAK/STAT Pathway, with a Focus on Ruxolitinib and Similar Agents, Resistance of Targeted Therapies Excluding Antibodies for Lymphomas IFN-?? induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells, Diabetologia Kombinierte SYK-JAK-Hemmung bei NHL, InFo Onkologie Syk inhibitors in clinical development for hematological malignancies, Journal of Hematology & Oncology